Gan & Lee Pharmaceuticals. has officially signed a 10-year Technology Transfer and Supply Agreement with Fiocruz, a public laboratory under the Brazilian Health Regulatory Agency (Anvisa), and Biomm, a leading Brazilian biopharmaceutical company. This marks the formal launch of Brazil's Parcerias para o Desenvolvimento Produtivo (PDP) project.
At the same time, Gan & Lee entered into a new Licensing and Supply Agreement with Biomm, securing cumulative orders of no less than RMB 3 billion over ten years, setting a new milestone on the foundation of strategic cooperation. As a core initiative to enhance the resilience of Brazil's public health system, the PDP project aims to introduce advanced international technologies while engaging local industries to fundamentally resolve supply gaps and improve access to essential medicines. Diabetes, one of the world's most prevalent chronic diseases, makes insulin an indispensable treatment option.
For Brazil, the largest country in Latin America by population, ensuring stable insulin supply is a particularly urgent priority. The tripartite collaboration focuses on this pressing public health need, with technology cooperation as the driving force, building a localized insulin manufacturing system and securing stable supply for patients. Complementary Roles: Building a "Technology + Localization" Cooperation Loop.
Each partner will play a distinct role to form a closed-loop model of "technology transfer-local production-long-term procurement." Gan & Lee bring over two decades of deep expertise in insulin R&D, manufacturing, and quality control, providing comprehensive technical support for localized insulin production in Brazil. Biomm, leveraging its in-depth understanding of local regulatory frameworks, healthcare systems, and market dynamics, ensures rapid compliance and market entry. Fiocruz, as both the technology recipient and the ultimate purchaser under the Brazilian Health Regulatory Agency ("Anvisa"), commits to long-term procurement over the next 10 years, adhering to the agreed-upon prices and volume specifications.
This three-way synergy will significantly accelerate the accessibility and affordability of high-quality insulin in Brazil. Phased Implementation: From Emergency Supply to Full Independence: The cooperation will be advanced in phases to achieve Brazil's long-term goal of insulin self-sufficiency: Initial phase: Gan & Lee will prioritize the supply of insulin glargine injection to help address urgent clinical demand in Brazil. Mid-term: Gan & Lee will transfer insulin glargine technology to Fiocruz, while continuing to supply both finished insulin glargine products and drug substances to Biomm.
Biomm will conduct local filling of insulin glargine injection and deliver it, together with compatible pen injectors, to Fiocruz. Long-term: The three parties will collaborate in professional talent development and the establishment of full-scale quality control systems to ensure that locally produced insulin meets international standards of quality, safety, and efficacy -- ultimately realizing Brazil's goal of insulin self-sufficiency.
